Marrone Bio Innovations

Marrone Bio Innovations, Inc., a biopesticide company, engages in the discovery, development, and marketing of natural products for weed, pest, and plant disease management. Its products include Regalia, a product that protects food and ornamental crops from fungal and bacterial diseases; GreenMatch EX, a postemergence herbicide for burndown weed control for organic growers; and GreenMatch, a burndown herbicide that controls various annual and perennial weeds. The Company also offers insecticides, herbicides, and products for controlling invasive zebra and quagga mussels in waterways. In addition, it finds naturally occurring microorganisms from habitats and develops them into products for controlling insects, weeds, nematodes, and plant diseases.

Company Growth (employees)
Type
Public
HQ
Davis, US
Founded
2006
Size (employees)
97 (est)+13%
Marrone Bio Innovations was founded in 2006 and is headquartered in Davis, US

Key People at Marrone Bio Innovations

Pam Marrone

Pam Marrone

Founder and CEO
Keith Pitts

Keith Pitts

Vice President, Regulatory Affairs

Marrone Bio Innovations Office Locations

Marrone Bio Innovations has an office in Davis
Davis, US (HQ)
2121 Second St.
Davis, US
1540 Drew Ave

Marrone Bio Innovations Data and Metrics

Marrone Bio Innovations Financial Metrics

Marrone Bio Innovations's revenue was reported to be $4.2 b in Q1, 2017
USD

Revenue (Q1, 2017)

4.2 b

Net income (Q1, 2017)

(7.6 b)

EBIT (Q1, 2017)

(5.9 b)

Market capitalization (18-Aug-2017)

28.2 m

Cash (31-Mar-2017)

1.8 m
Marrone Bio Innovations's current market capitalization is $28.2 m.
USDFY, 2013Y, 2014FY, 2015FY, 2016

Revenue

14.5 m1.1 m9.8 m14 m

Revenue growth, %

(92%)793%43%

General and administrative expense

18.5 m

Operating expense total

32.8 m15.2 m40 m28.2 m

EBIT

(29 m)(15.5 m)(39.5 m)(23.7 m)

EBIT margin, %

(200%)(1416%)(403%)(168%)

Interest expense

6 m669 k2.8 b(2.9 m)

Interest income

49 k17 k51 m37 m

Pre tax profit

(28.5 m)(16.2 m)(43.7 m)(31.1 m)

Net Income

(28.5 m)(16.2 m)(43.7 m)(31.1 m)
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.8 m3.6 m2.1 m3.4 m2.5 m2.7 m5 m3.6 m4.2 b

General and administrative expense

6.3 m6 m7.9 m7.4 m5.3 m5.5 m4.5 m3.8 m5.3 b

Operating expense total

6.3 m6 m7.9 m7.4 m5.3 m5.5 m4.5 m3.8 m5.3 b

EBIT

(9.5 m)(9.5 m)(11.3 m)(10.4 m)(8.6 m)(7.5 m)(4.9 m)(5.3 m)(5.9 b)

EBIT margin, %

(340%)(261%)(547%)(309%)(348%)(279%)(97%)(145%)(142%)

Interest expense

(773 k)(825 k)(669 k)(659 k)(687 k)(1 m)(759 k)(755 k)(636 m)

Interest income

10 k11 k9 k6 k14 k15 k10 k8 k1 m

Pre tax profit

(10.2 m)(10.4 m)(11.9 m)(11 m)(9.8 m)(9.3 m)(6.8 m)(7.2 m)(7.6 b)

Net Income

(10.2 m)(10.4 m)(11.9 m)(11 m)(9.8 m)(9.3 m)(6.8 m)(7.2 m)(7.6 b)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

24.5 m35.3 m19.8 m9.6 m

Accounts Receivable

6.2 m1.8 m2.3 m3.6 m

Inventories

1.7 m1.3 m1.3 m8.5 m

Current Assets

58.7 m54.7 m36 m26.9 m

PP&E

9.4 m20.2 m18.4 m17.3 m

Total Assets

68.9 m77.2 m71.8 m46 m

Accounts Payable

4.5 m5.8 m2 m1.4 m

Current Liabilities

11.7 m31.2 m12.9 m15.2 m

Total Liabilities

76.2 m

Additional Paid-in Capital

147.2 m193.1 m201.6 m204.5 m

Retained Earnings

(105.4 m)(159.8 m)(203.6 m)(234.6 m)

Total Equity

41.8 m33.2 m(2 m)(30.2 m)

Financial Leverage

1.6 x2.3 x-35.5 x-1.5 x
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

21.3 m57.6 m22.4 m12.2 m27.8 m9.8 m21.2 m16 m1.8 m

Accounts Receivable

7.2 m4.1 m2.2 m3 m1.4 m4.7 m4.5 m2.1 m8.1 m

Inventories

12.8 m12.5 m11.8 m10.6 m9.8 m8.6 m8 m8.4 m8.1 m

Current Assets

47 m80.1 m41.1 m30.2 m43.4 m28.1 m37.8 m30.6 m24.4 m

PP&E

15.8 m18.5 m20.1 m20.1 m19.3 m19.1 m18.5 m17.9 m16.9 m

Total Assets

63.5 m101 m63.4 m52.5 m80.1 m64 m58.2 m50.2 m43 m

Accounts Payable

8.6 m5.2 m4.1 m3.2 m1 m2.6 m2.2 m2.2 m3 m

Current Liabilities

14.5 m11.4 m28.6 m27.7 m11.5 m13.4 m13.8 m12.6 m18.6 m

Additional Paid-in Capital

149.6 m191.1 m194.2 m195.3 m200.6 m202.2 m202.9 m203.6 m205.1 m

Retained Earnings

(115.7 m)(126.1 m)(171.8 m)(182.7 m)(192.5 m)(212.9 m)(219.6 m)(226.8 m)(242.3 m)

Total Equity

34 m65 m22.4 m12.5 m8.1 m(10.7 m)(16.7 m)(23.2 m)(37.2 m)

Financial Leverage

1.9 x1.6 x2.8 x4.2 x9.9 x-6 x-3.5 x-2.2 x-1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.5 m)(16.2 m)(43.7 b)(31.1 m)

Depreciation and Amortization

976 k2.2 m

Accounts Receivable

(3.4 m)1.8 m(1.2 m)

Inventories

(6.8 m)1.3 m582 k

Accounts Payable

1.7 m5.8 m(588 k)

Cash From Operating Activities

(34 m)(15.5 m)(24.3 m)

Purchases of PP&E

(4 m)(209 k)

Cash From Investing Activities

(17.7 m)(209 k)

Long-term Borrowings

(9.4 m)(260 k)

Cash From Financing Activities

66.1 m14.3 m
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.2 m)(10.4 m)(11.9 m)(11 m)(9.8 m)(9.3 m)(6.8 m)(7.2 m)(7.6 b)

Accounts Receivable

7.2 m4.1 m2.2 m3 m1.4 m4.7 m4.5 m2.1 m8.1 m

Accounts Payable

8.6 m5.2 m4.1 m3.2 m1 m2.6 m2.2 m2.2 m3 m
USDY, 2017

Revenue/Employee

45.4 m

Financial Leverage

-1.2 x

Marrone Bio Innovations Market Value History

Marrone Bio Innovations Job Categories

Traffic Overview of Marrone Bio Innovations

Marrone Bio Innovations Online and Social Media Presence

Marrone Bio Innovations News and Updates

To Save Florida’s Famous Oranges, Scientists Race to Weaponize a Virus

Florida's orange growers are running out of time to find a cure to the deadly "citrus greening" disease. A spinach gene-carrying virus might be their lifeline. The post To Save Florida's Famous Oranges, Scientists Race to Weaponize a Virus appeared first on WIRED.

BRIEF-Marrone Bio Innovations - Regalia Rx Biofungicide approved in Canada

* Regalia RX Biofungicide approved in Canada for use on wheat and soybeans Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Marrone Bio Innovations Company Life and Culture

You may also be interested in